Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24.

PMID:
31339357
2.

Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States.

Kelly RJ, Turner R, Chen YW, Rigas JR, Fernandes AW, Karve S.

J Oncol Pract. 2019 Aug;15(8):e717-e727. doi: 10.1200/JOP.18.00762. Epub 2019 Jun 25.

PMID:
31237806
3.

A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.

Dragnev KH, Whyman JD, Hahn CK, Kebbekus PE, Kokko SF, Bhatt SM, Rigas JR.

J Thorac Dis. 2018 Sep;10(9):5531-5537. doi: 10.21037/jtd.2018.09.10.

4.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.

5.

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.

Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY.

Cancer. 2015 Dec 1;121(23):4165-72. doi: 10.1002/cncr.29636. Epub 2015 Aug 26.

6.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.

Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA.

Br J Cancer. 2014 Feb 4;110(3):602-8. doi: 10.1038/bjc.2013.735. Epub 2013 Nov 28.

7.

VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.

Zhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J; China Clinical Trials Consortium.

J Thorac Dis. 2013 Oct;5(5):578-84. doi: 10.3978/j.issn.2072-1439.2012.02.05.

8.

Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.

Schweppe DK, Rigas JR, Gerber SA.

J Proteomics. 2013 Oct 8;91:286-96. doi: 10.1016/j.jprot.2013.07.023. Epub 2013 Aug 2.

9.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Review.

10.

Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Black CC, Turk MJ, Dragnev K, Rigas JR.

Lung. 2013 Jun;191(3):265-70. doi: 10.1007/s00408-013-9455-7. Epub 2013 Mar 15.

PMID:
23494387
11.

Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.

Wood MD, Zaki BI, Gordon SR, Sutton JE Jr, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR.

J Thorac Oncol. 2013 Apr;8(4):487-94. doi: 10.1097/JTO.0b013e3182829bf3.

12.

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.

Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon GB, Dmitrovsky E, Dragnev KH.

Chemotherapy. 2012;58(4):321-9. doi: 10.1159/000343165. Epub 2012 Nov 12.

13.

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.

Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR.

Expert Opin Biol Ther. 2011 Dec;11(12):1663-8. doi: 10.1517/14712598.2011.627850. Epub 2011 Oct 13. Review.

PMID:
21995322
14.

Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.

Marotti JD, Schwab MC, McNulty NJ, Rigas JR, DeLong PA, Memoli VA, Tsongalis GJ, Padmanabhan V.

Diagn Cytopathol. 2013 Jan;41(1):15-21. doi: 10.1002/dc.21749. Epub 2011 Jun 16.

PMID:
21681971
15.

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E.

Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376.

16.

Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.

Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maître A, Gandara D, Johnson DH, Rigas JR, Seymour L, Shepherd FA.

J Thorac Oncol. 2011 Jan;6(1):139-47. doi: 10.1097/JTO.0b013e3181fd83a4.

17.

Pemetrexed in advanced non-small-cell lung cancer.

Fuld AD, Dragnev KH, Rigas JR.

Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560. Review.

PMID:
20446853
18.

A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.

Dragnev KH, Hardin SB, Pipas JM, Davis TH, Rigas JR.

Chemotherapy. 2010;56(2):135-41. doi: 10.1159/000313526. Epub 2010 Apr 20.

PMID:
20407240
19.

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.

Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA.

Clin Cancer Res. 2010 Mar 15;16(6):1938-49. doi: 10.1158/1078-0432.CCR-08-3328. Epub 2010 Mar 9.

20.

Lung cancer in a U.S. population with low to moderate arsenic exposure.

Heck JE, Andrew AS, Onega T, Rigas JR, Jackson BP, Karagas MR, Duell EJ.

Environ Health Perspect. 2009 Nov;117(11):1718-23. doi: 10.1289/ehp.0900566. Epub 2009 Jul 2.

21.

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R.

Lung Cancer. 2010 Apr;68(1):89-93. doi: 10.1016/j.lungcan.2009.05.009. Epub 2009 Jun 12.

PMID:
19524318
22.

Current treatment paradigms for locally advanced non-small cell lung cancer.

Rigas JR, Kelly K.

J Thorac Oncol. 2007 Jun;2 Suppl 2:S77-85. Review.

23.

Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.

Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, Zembryki D, Leopold LH.

Am J Clin Oncol. 2007 Jun;30(3):245-51.

PMID:
17551300
24.

Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.

Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA; National Cancer Institute of Canada and Intergroup Study JBR.10.

J Clin Oncol. 2007 Apr 20;25(12):1553-61.

PMID:
17442999
25.

A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.

Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E.

Clin Cancer Res. 2007 Mar 15;13(6):1794-800.

26.

Uncovering novel targets for cancer chemoprevention.

Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, Nugent W, Rigas JR, Kitareewan S, Freemantle S, Dmitrovsky E.

Recent Results Cancer Res. 2007;174:235-43. Review.

PMID:
17302201
27.

Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.

Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L.

Lung Cancer. 2007 Mar;55(3):357-63. Epub 2006 Dec 1.

PMID:
17141357
28.

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.

Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators.

Clin Appl Thromb Hemost. 2006 Oct;12(4):389-96.

PMID:
17000884
29.
30.
31.

Bexarotene and erlotinib for aerodigestive tract cancer.

Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E.

J Clin Oncol. 2005 Dec 1;23(34):8757-64.

PMID:
16314636
32.

Docetaxel in the treatment of esophageal cancer.

Rigas JR, Dragnev KH, Bubis JA.

Semin Oncol. 2005 Apr;32(2 Suppl 4):S39-51. Review.

PMID:
16015553
33.

A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.

Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE.

J Neurooncol. 2005 Feb;71(3):301-5.

PMID:
15735921
34.

Nonclassical retinoids and lung carcinogenesis.

Dragnev KH, Petty WJ, Ma Y, Rigas JR, Dmitrovsky E.

Clin Lung Cancer. 2005 Jan;6(4):237-44. Review.

PMID:
15694016
35.

Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.

Rigas JR, Dragnev KH.

Oncologist. 2005 Jan;10(1):22-33. Review.

36.

Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.

Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E.

Clin Cancer Res. 2004 Nov 15;10(22):7547-54.

37.
38.

Chlorpheniramine for motion sickness.

Buckey JC, Alvarenga D, Cole B, Rigas JR.

J Vestib Res. 2004;14(1):53-61.

PMID:
15156097
39.

Docetaxel and gemcitabine: a nonplatinum combination for non small-cell lung cancer.

Olszanski AJ, Rigas JR.

Clin Lung Cancer. 2000 Apr;1 Suppl 1:S15-9.

PMID:
14725737
40.

The role of docetaxel in nonplatinum-based combination chemotherapy for non-small-cell lung cancer.

Petty WJ, Rothmann J, Dragnev KH, Rigas JR.

Clin Lung Cancer. 2002 May;3 Suppl 2:S12-6.

PMID:
14720342
41.

Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, Rhodes GR, Rigas JR.

Clin Cancer Res. 2003 Mar;9(3):1077-82.

42.

Regression of metastatic non-small cell lung cancer with low molecular weight heparin.

Loynes JT, Zacharski LR, Rigas JR.

Thromb Haemost. 2002 Oct;88(4):686. No abstract available.

PMID:
12362244
43.

IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.

Hirsch FR, Bunn PA Jr, Dmitrovsky E, Field JK, Franklin WA, Greenberg RE, Hansen HH, Henschke CI, Rigas JR, Smith RA, Toennesen P, Mulshine JL.

Lung Cancer. 2002 Sep;37(3):325-44. No abstract available.

PMID:
12234703
44.
45.

Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.

Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD, Hong WK.

J Clin Oncol. 2001 May 15;19(10):2626-37.

PMID:
11352954
46.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.

Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG.

Semin Oncol. 2001 Feb;28(1 Suppl 2):4-9. Review.

PMID:
11284623
47.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials.

Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG.

Semin Oncol. 2001 Feb;28 Suppl 2:4-9.

PMID:
28140080
48.

The retinoids and cancer prevention mechanisms.

Dragnev KH, Rigas JR, Dmitrovsky E.

Oncologist. 2000;5(5):361-8. Review.

49.

Hypertensive crisis following meperidine administration and chemoembolization of a carcinoid tumor.

Balestrero LM, Beaver CR, Rigas JR.

Arch Intern Med. 2000 Aug 14-28;160(15):2394-5. No abstract available.

PMID:
10927742
50.

Recent advances in cancer chemotherapy.

Ornstein DL, Pipas JM, Rigas JR.

Acad Radiol. 1999 Nov;6(11):696-705. Review. No abstract available.

PMID:
10894074

Supplemental Content

Loading ...
Support Center